clinical trial · NCT05964413
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
Pyoderma GangrenosumvilobelimabPlacebo
brief summary
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
started
Nov 1, 2023
primary completion
Jul 11, 2025
completion
Jul 11, 2025
last updated
Nov 4, 2025
official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol